生物科技 1


​The pharma business

A better pill from China


Chinese pharma firms are starting to develop new drugs for the global


  1. WALK into the Shanghai laboratories of Chi-Med, a biotech firm, and
    you encounter the sort of shiny, cutting-edge facilities common
    in any major pharma company in America, Europe or Japan.
    Chi-Med(和黄药业)has just had positive results in a late-stage
    trial of its drug for colorectal cancer, which is called
    Fruquintinib. If the drug is approved both in China and in Western
    markets it could be the very first prescription drug to be designed
    and developed entirely in China that will be on a path to global
    1)走进新加坡和黄药业的实验室,一家生物技术集团,你会不期而遇那三个在欧洲和美洲或东瀛其他大型制药公司都很广泛的闪光、尖端的配备。香港和记黄埔股份两合公司中中原人民共和国药业在直肠癌药品的末尾试验是中性(neuter gender)结果,那种药物被称为呋喹替尼。即便该药在中原和在天堂市场都被批准(生产),它恐怕是完全在华夏被规划和支出的第2批处方药,中国(药业)将走向全球商业化道路。

  2. Given China’s ageing population, higher incomes and rising demand
    for health care it is clear why innovation in drugs is a priority
    for the country. Its national market for drugs has grown rapidly in
    recent years to become the world’s second-largest. It could grow
    from $108bn in 2015 to around 167bn dollars by 2020, according to an
    estimate from America’s Department of Commerce. By comparison,
    America spends about $400bn a year on drugs.

  3. Chinese firms mainly sell cheap,** generic medicines** that earn
    only razor-thin margins. The pharma industry is extremely
    fragmented, with thousands of tiny manufacturers and distributors.
    That helps explain the limited amount of finance that is available
    for investment in new medicines. Most Chinese pharma firms devote
    less than 5% of sales to R&D, according to a report last year from
    the World Health Organisation (big global drug firms typically spend
    14%-18% of sales on R&D). And the bulk of that spending goes to
    research into generics.


  1. 生物科技,But things are changing quickly. The government is encouraging the
    industry to consolidate, chiefly by raising standards for the
    quality of new medicines. It is also improving the country’s
    regulatory infrastructure, which should make it more efficient, and
    faster, to develop drugs. The value of deals in the health-care
    sector has been increasing as a result. ChinaBio, a research firm,
    reckons that over $40bn of foreign and local money went into the
    life sciences in China in 2016. In the same year just three Chinese
    biotech firms—CStone, Innovent and Ascletis—together raised more
    than $500m of financing.
    4)但全部正在快速转移。政坛在鼓励制药企合并,首要通过抓牢新药品质量标准的艺术。它也在校勘国家的监禁基础设备,这应该使它更神速、更迅捷地开发药物。因此,医疗保健行业的贸易价值不断充实。一家U.S.研讨集团ChinaBio估计,二零一四年超越400亿欧元的大世界资金进入中华的生命科学(产业)。在一如既往年,仅三家中夏族民共和国生物科学技术集团——东京基石药业、马尔默信达生物以及阿塞拜疆巴库歌礼生物科技(science and technology)有限公司——就一同筹集了超过5亿台币融资。

  2. Another boost is the arrival of talent from abroad, whether
    Chinese-born executives returning with a Western education or
    Westerners with experience of multinational pharmaceutical firms.
    Christian Hogg, the boss of Chi-Med—which was founded in 2000, has
    eight drugs in clinical development and listed on the NASDAQ stock
    exchange in 2016—used to work at Procter & Gamble, a global
    consumer-goods firm. Samantha Du, the firm’s very first scientific
    officer, was formerly an executive at Pfizer, an American pharma
    giant. Now known as the godmother of Chinese biopharma, she used to
    manage health-care investments for Sequoia Capital, a Silicon Valley
    venture-capital firm. In 2013 she helped found Zai Lab, which
    licenses late-stage drugs from Western pharma companies to
    develop and sell in China. Zai Lab also aims to develop innovative
    medicines in immuno-oncology.
    5)另2个有助于要素是异域人才的来到,无论是接受西方教育又回国的华夏管理人士,照旧有跨国制药企业经历的西方职员。贺隽是树立于两千年的和黄药业的COO娘,该铺面有着医疗开发的各类药品,并于二零一五年在纳斯达克股交所上市。他曾在大地消费品公司宝洁企业管理办公室事。该公司的首先位专业出身的COO杜莹曾是U.S.制药业巨头辉瑞制药集团的执行官。今后他被称呼和浩特中学夏族民共和国生物制药的教母,她曾为一家硅谷风险投资集团——红杉资本管理医疗保健投资。二零一一年她扶持创设(总部位于北京的生物科技(science and technology)公司)再鼎医药,该集团从西方制药公司取得前期药物许可证以在中原研究开发并销售。再鼎医药还致力于付出免疫肿瘤学地点的换代药物。

  3. Another firm attracting attention is BeiGene, an oncology firm based
    in Beijing, which has four clinical-stage drug candidates and which
    raised $158m in an IPO last year. Chi-Med’s Fruquintinib may even be
    beaten in the race to approval in America and Japan by a cancer drug
    called Epidaza from Chipscreen Biosciences of Shenzhen. China
    approved it in 2015.
    6)另一家引人关怀的是总部放在东京、从事抗癌药研发的百济神州生物制药公司,它有两种医疗阶段的候选药物,并在上年第①遍公开募股到1.58亿卢比。香港和记黄埔有限义务公司中中原人民共和国药业的呋喹替尼可能在United States和东瀛得到许可的竞赛中被布拉迪斯拉发微芯生物科学和技术的抗癌药物Epidaza所打败。而中华于二零一五年就特许了它(前者的研究开发)。

  4. It is too early to say whether these innovative firms will remain
    rarities. Only a few large ones have emerged, since the industry
    is resisting consolidation. But the size of the local market will
    itself help the industry grow. And developing a drug in China is far
    cheaper than it is in America or Europe. Given the outrage at the
    high cost of drugs in America, in particular, there is every
    for Chinese firms to develop medicines for the global

壹 、鉴于中夏族民共和国的老龄化人口、更高个人收入和不止升起的正规护理供给,为啥在药物方面包车型大巴换代成为这几个国度的当务之急就清楚了。

贰 、另3个促进因素是国外人才的来临,无论是接受西方教育又回国的炎黄管理人士,仍旧有跨国制药公司经历的极乐世界职员。

③ 、尤其是,鉴于美利哥药物价格昂贵引起愤怒,中中原人民共和国有集团业为海内外国商人场开发药品的动机十足